Zobrazeno 1 - 10
of 133
pro vyhledávání: '"Laurent, Salphati"'
Autor:
Rocky Diegmiller, Laurent Salphati, Bruno Alicke, Timothy R. Wilson, Thomas J. Stout, Marc Hafner
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 9, Pp 1183-1193 (2022)
Abstract A major challenge in oncology drug development is to elucidate why drugs that show promising results in cancer cell lines in vitro fail in mouse studies or human trials. One of the fundamental steps toward solving this problem is to better p
Externí odkaz:
https://doaj.org/article/a27b16f4e3af4e099d40f81f20515d08
Autor:
Le An, Tom De Bruyn, Jodie Pang, Savita Ubhayakar, Laurent Salphati, Xing Zhang, Liling Liu, Ruina Li, Bryan Chan, Anwesha Dey, Elizabeth S. Levy
Publikováno v:
Pharmaceuticals, Vol 17, Iss 2, p 179 (2024)
Early stage chemical development presents numerous challenges, and achieving a functional balance is a major hurdle, with many early compounds not meeting the clinical requirements for advancement benchmarks due to issues like poor oral bioavailabili
Externí odkaz:
https://doaj.org/article/bad1620eb0dc40749208e8e8c2838fb1
Autor:
Shuguang Ma, Sungjoon Cho, Srikumar Sahasranaman, Weiping Zhao, Jodie Pang, Xiao Ding, Brian Dean, Bin Wang, Jerry Y. Hsu, Joseph Ware, Laurent Salphati
Publikováno v:
Drug Metabolism and Disposition. 51:436-450
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fdf16c475c39101aef67df335d26c42f
https://doi.org/10.1124/dmd.122.001096
https://doi.org/10.1124/dmd.122.001096
Autor:
Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-12 (2018)
Abstract Background Indoleamine-2,3-dioxygenase 1 (IDO1) catalyzes the oxidation of tryptophan into kynurenine and is partially responsible for acquired immune tolerance associated with cancer. The IDO1 small molecule inhibitor navoximod (GDC-0919, N
Externí odkaz:
https://doaj.org/article/fa3f41ad888d41f5a1c759f8b6fa21b2
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
RTK activity plays a key role in regulating p110a degradation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3f61f91c6eba4539d57e9ffe438944
https://doi.org/10.1158/2159-8290.22540279
https://doi.org/10.1158/2159-8290.22540279
Autor:
Lori S. Friedman, Anwesha Dey, Donald S. Kirkpatrick, Steven T. Staben, Shiva Malek, Alan G. Olivero, Timothy P. Heffron, Laurent Salphati, Gail D. Lewis Phillips, Emile G. Plise, Jonathan Cheong, Jeffrey J. Wallin, Jane Guan, Nicholas Endres, Stephen Schmidt, Eric Stawiski, William F. Forrest, Lilian Phu, Rebecca Hong, Michelle A. Nannini, Deepak Sampath, Mark Merchant, Jason Oeh, Marc Hafner, Emily J. Hanan, Kyle A. Edgar, Kyung W. Song
PIK3CA is one of the most frequently mutated oncogenes; the p110a protein it encodes plays a central role in tumor cell proliferation. Small-molecule inhibitors targeting the PI3K p110a catalytic subunit have entered clinical trials, with early-phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fd67c192262a4b6f3e1d058d9266830
https://doi.org/10.1158/2159-8290.c.6549343
https://doi.org/10.1158/2159-8290.c.6549343
Autor:
Lori S. Friedman, Marcia Belvin, Deepak Sampath, Mark R. Lackner, Leanne Ross, Robert Kassees, Letitia Lensun, Sonal Patel, Jill M. Spoerke, Carol O'Brien, Daniel P. Sutherlin, Alan G. Olivero, Laurent Salphati, Jodie Pang, Jim Nonomiya, Cristina Lewis, John D. Lesnick, Leslie Lee, Wei Wei Prior, Megan Berry, Jane Guan, Kyle A. Edgar, Jeffrey J. Wallin
PDF file - 894K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::136e199abb6bc063918f64da058aa806
https://doi.org/10.1158/1535-7163.22496520
https://doi.org/10.1158/1535-7163.22496520
Autor:
José Baselga, Daniel D. Von Hoff, Jerry Y. Hsu, Hema Parmar, Huan Jin, Ray S. Lin, Laurent Salphati, Deepak Sampath, Heidi M. Savage, Sandra M. Sanabria Bohorquez, Joseph A. Ware, Timothy R. Wilson, Ramesh K. Ramanathan, Ian Krop, Dejan Juric
Supplementary Table S1. Patient Demographics and Disease Characteristics. Supplementary Table S2. Treatment-Related Adverse Events of Grade 3 or Higher Observed in either Cycle 1 or Cycle greater than or equal to 2. Supplementary Table S3. Adverse Ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08231e12877ec97d91ac400e1e431122
https://doi.org/10.1158/2159-8290.22532083.v1
https://doi.org/10.1158/2159-8290.22532083.v1
Autor:
Lori S. Friedman, Marcia Belvin, Deepak Sampath, Mark R. Lackner, Leanne Ross, Robert Kassees, Letitia Lensun, Sonal Patel, Jill M. Spoerke, Carol O'Brien, Daniel P. Sutherlin, Alan G. Olivero, Laurent Salphati, Jodie Pang, Jim Nonomiya, Cristina Lewis, John D. Lesnick, Leslie Lee, Wei Wei Prior, Megan Berry, Jane Guan, Kyle A. Edgar, Jeffrey J. Wallin
Alterations of the phosphoinositide-3 kinase (PI3K)/Akt signaling pathway occur broadly in cancer via multiple mechanisms including mutation of the PIK3CA gene, loss or mutation of phosphatase and tensin homolog (PTEN), and deregulation of mammalian
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::344448ff3a06fe2f5d7081d2a898c2c2
https://doi.org/10.1158/1535-7163.c.6535305
https://doi.org/10.1158/1535-7163.c.6535305
Autor:
Todd W. Miller, Alan R. Eastman, Jonathan D. Marotti, Lionel D. Lewis, Darcy Bates, Eugene Demidenko, Michelle A. Nannini, Xiaolin Zhang, Jodie Pang, Laurent Salphati, Jennifer R. Bean, Stephanie C. Liu, Kevin Shee, Lloye M. Dillon, Sarah R. Hosford, Wei Yang
Purpose: Phosphatidylinositol 3-kinase (PI3K) inhibitors are being developed for the treatment of estrogen receptor α (ER)–positive breast cancer in combination with antiestrogens. Understanding the temporal response and pharmacodynamic effects of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11f086589c547a57eaef4c868b65fbd0
https://doi.org/10.1158/1078-0432.c.6523695.v1
https://doi.org/10.1158/1078-0432.c.6523695.v1